Citigroup has upgraded Penumbra Inc (PEN) to a Buy rating from Neutral, indicating a more positive outlook on the company's future prospects. This decision, made on December 10, 2025, comes as Penumbra demonstrates strong fundamentals and consistent business performance.
Headquartered in Alameda, California, Penumbra specializes in thrombectomy solutions, designing and manufacturing innovative medical products aimed at improving clinical outcomes. The company has a market capitalization of $11.4 billion and reported a trailing twelve-month price-to-earnings ratio of 69.30, with earnings per share at $4.14.
Looking ahead, Penumbra is scheduled to announce its next earnings on July 27, 2026, with analysts estimating earnings per share of $1.21 and revenue of $391.3 million. Recent earnings performance has been robust, with Q3 2025 EPS of $0.97 surpassing estimates by 4.2%.
The upgrade underscores growing confidence in Penumbra’s strategic direction, as reflected in the current analyst consensus, which shows 8 Strong Buy, 12 Buy, and 4 Hold ratings among 24 analysts. As market conditions evolve, such analyst ratings may shift, presenting investors with varied perspectives on the company's trajectory.